Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
News
A “block-and-replace” regimen of corticosteroid therapy can be used to manage COVID-19 in people with Cushing’s disease, a new report highlights. The report, “COVID-19 and Cushing’s disease in a patient with ACTH-secreting pituitary carcinoma,” was published in the journal Endocrinology, Diabetes and Metabolism Case Reports.
People with Cushing’s disease have a high risk of being deficient in vitamin D, but taking supplements can improve those levels, a new study indicates. Results also showed that lower vitamin D levels are associated with higher levels of cortisol, a stress hormone that is elevated in Cushing’s. The…
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like to live with a rare disease, including conversations about advocacy, mental health, survivor’s guilt, treatment of minority patients, and more. The Monday event, “A…
A rare disease puts an economic burden on the patients, families, and caregivers that it affects, and will no doubt be an integral part of discussions on Rare Disease Day 2022, which brings international awareness about the more than 300 million people living with rare disorders. Part of that…
There are sets of microRNAs that may be used as markers for inherited or newly arising primary macronodular adrenal hyperplasia (PMAH), a rare cause of Cushing’s syndrome, a small study found. According to researchers, these microRNAs — short RNA molecules that help control the activity of certain genes — also…
The nonprofit RARE-X is creating an easily-accessible, centralized data hub for all rare disease patient data that can help researchers answer questions about existing disorders, discover new ones, and work toward finding treatments. It was spun out of the work that Nicole Boice, founder and chief engagement officer of…
Corcept Therapeutics is on track to ask the U.S. Food and Drug Administration (FDA) to approve the investigational therapy relacorilant to treat Cushing’s syndrome by the middle of next year, the company announced. Cushing’s syndrome is characterized by excessive levels of the stress hormone cortisol, which causes a range of…
It’s been nearly a year since the EveryLife Foundation for Rare Diseases released its expansive report finding the total economic burden of rare disorders in the U.S. to be nearly $1 trillion.
Patients with Cushing’s syndrome are almost two times more likely to develop sleep apnea — a condition in which a person ceases to breathe for at least 10 seconds while sleeping — than the general population, according to a U.S. database study. These findings highlight the importance of screening for…
Recent Posts
- Raising awareness of the mental health effects of Cushing’s disease
- Older Cushing’s patients more likely to need long-term steroids after surgery
- CSRF goals for Cushing’s awareness month: Educate, fund vital research
- Before meds, Cushing’s disease resulted in the loss of my period
- Woman’s Cushing’s diagnosis missed before weight-loss surgery: Report
- How living with Cushing’s disease is like a modern-day ‘Moby-Dick’
- Negative MRI linked to lower surgery success rate in Cushing’s disease
- Woman’s ultra rare spinal condition caused by Cushing’s disease: Report
- I find myself struggling to manage the complications of Cushing’s disease
- Urine test improves reliability of Cushing’s syndrome diagnosis: Study